文献速递心境障碍

重度抑郁症的服务覆盖:2021年204个国家和地区的最低限度充分治疗估计率

Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021.
PubMed 文献 · Lancet Psychiatry · 2024-01-01

该研究基于32项研究、31个国家的145个估计值,采用网络Meta分析和贝叶斯Meta回归(DisMod-MR 2.1)估计2021年全球重度抑郁症患者接受最低限度充分治疗(MAT)的比例。全球MAT覆盖率为9.1%(95%不确定区间7.2-11.6),高收入地区最高(27.0%),撒哈拉以南非洲最低(2.0%)。作者认为多数重度抑郁症患者未获得MAT,需扩大有效干预策略。

要点

  • 2021年全球重度抑郁症患者MAT覆盖率为9.1%(95%不确定区间7.2-11.6)。
  • 高收入地区MAT覆盖率27.0%,撒哈拉以南非洲仅2.0%,西撒哈拉以南非洲最低1.8%。
  • 7个国家MAT覆盖率超过30%,90个国家低于5%。

核心结论

  • 尽管现有数据存在许多缺口,估计显示全球大多数重度抑郁症患者未接受最低限度充分治疗(MAT)。
  • 服务必须改善以达到更好地满足重度抑郁症患者心理健康需求的全球覆盖率。
  • 作者认为应紧急关注扩大有效干预策略,尤其是在低收入和中等收入国家,并进一步研究更高质量的重度抑郁症治疗方案。

研究设计与样本

  • 从现有综述中识别评估普通人群重度抑郁症及该人群卫生服务利用的精神健康调查,提取MAT、抗抑郁药使用或任何精神健康服务使用的估计值。
  • 后两者通过网状Meta分析调整以反映可能的MAT率,调整后的MAT估计值通过贝叶斯Meta回归(DisMod-MR 2.1工具)分析,按年龄、性别、地点和年份估计重度抑郁症患者的MAT覆盖率。
  • 分析数据集包括来自32项研究的145个估计值,覆盖31个国家、14个地区和6个超级区域;最终MAT估计值按全球重度抑郁症患者的年龄和性别分布进行标准化。

主要发现

  • 2021年全球重度抑郁症患者接受MAT的比例为9.1%(95%不确定区间7.2-11.6),女性为10.2%(8.2-13.1),男性为7.2%(5.7-9.3)。
  • MAT覆盖率在高收入地区最高(27.0% [21.7-34.4]),其中澳大拉西亚最高(29.2% [21.4-40.8])。
  • MAT覆盖率在撒哈拉以南非洲最低(2.0% [1.5-2.6]),其中西撒哈拉以南非洲最低(1.8% [1.4-2.5])。
  • 估计有7个国家(澳大利亚、比利时、加拿大、德国、荷兰、韩国和瑞典)MAT覆盖率超过30%,而90个国家估计覆盖率低于5%。

关键数值与推荐

  • MAT定义为药物治疗(1个月药物加4次就诊医生)或心理治疗(8次就诊任何专业人员)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出可用数据存在许多缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Access to effective treatment for major depressive disorder remains limited and difficult to track across place and time. We analysed the available data on minimally adequate treatment (MAT) for major depressive disorder globally with the aim of providing a useful metric against which to monitor national responses to the growing public health burden imposed by major depressive disorder. METHODS: MAT was defined as pharmacotherapy (1 month of medication, plus four visits to a medical doctor) or psychotherapy (eight visits with any professional). From existing reviews, we identified mental health surveys that assessed major depressive disorder within the general population as well as health service uptake by individuals with major depressive disorder. Data by ethnicity were not available. Estimates of MAT, antidepressant use, or use of any mental health service were extracted. The latter two estimates were adjusted to reflect likely MAT rates via a network meta-analysis. Adjusted MAT estimates were analysed via a Bayesian meta-regression using the Disease Modelling Meta-Regression (DisMod-MR 2.1) tool. This analysis estimated MAT coverage among people with major depressive disorder by age, sex, location, and year. Final MAT estimates were standardised by age and sex against the existing age and sex distribution of people with major depressive disorder globally. People with lived experience were involved in the design, preparation, interpretation, and writing of this manuscript. FINDINGS: The analysed dataset included 145 estimates from 32 studies, covering 31 countries, 14 regions, and six super-regions. The proportion of people with major depressive disorder receiving MAT globally in 2021 was 9·1% (95% uncertainty interval 7·2-11·6), with 10·2% (8·2-13·1) of females and 7·2% (5·7-9·3) of males with major depressive disorder receiving MAT. MAT coverage was highest in high-income locations (27·0% [21·7-34·4]), with Australasia having the highest rate (29·2% [21·4-40·8]). MAT coverage was lowest in sub-Saharan Africa (2·0% [1·5-2·6]), within which western sub-Saharan Africa (1·8% [1·4-2·5]) had the lowest coverage. Seven countries (Australia, Belgium, Canada, Germany, the Netherlands, South Korea, and Sweden) were estimated to have MAT coverage exceeding 30%, while 90 countries were estimated to have coverage lower than 5%. INTERPRETATION: Despite many gaps in the available data, estimates show that, globally, most individuals with major depressive disorder do not receive MAT. Services must improve to reach a global coverage that better meets the mental health needs of those with major depressive disorder. Urgent attention should be given to the scale-up of effective intervention strategies, especially in low-income and middle-income countries, as well as further research into better quality treatment options for major depressive disorder. We present a means by which the MAT gap for major depressive disorder can be quantified, to monitor and inform action by governments and international partners. FUNDING: Queensland Health and the Bill & Melinda Gates Foundation.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Santomauro DF, Vos T, Whiteford HA, et al. Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021. Lancet Psychiatry. 2024. PMID: 39572105. doi:10.1016/S2215-0366(24)00317-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。